ASML to 2035 still has a rare long-term strategic franchise, but the long-range stock outlook should be framed with explicit revenue, margin, and valuation assumptions rather than pure enthusiasm.

ASML to 2030 still has one of the clearest strategic runways in European technology, but long-term targets should be anchored in official demand and margin signals rather than pure AI enthusiasm.

Eli Lilly still has a credible path to a materially larger business by 2030, but the stock is no longer cheap enough for optimism alone. The central question is whether obesity, diabetes, and pipeline ...

Why Ethereum could fall next, with verified macro and market-structure risks, downside triggers, and review checkpoints.

DAX 40 outlook with quantified scenarios, earnings and valuation context, macro triggers, and institutional views for 2027.

The decade thesis is that DAX remains Europe's premier industrial and software beta. A decade from now, the most important question is whether Germany emer ...

Ever juggled work emails, personal shopping, and family streaming on the same browser? 😩 Microsoft Edge multiple profiles solve that chaos, letting you keep everything organized while Edge profiles ...

Microsoft stock analysis with current valuation, earnings, AI exposure, macro context, and scenario-based ranges backed by current sources.

Base case: gold can still grind higher from here because central-bank buying, bar-and-coin demand, and persistent geopoli ...

AstraZeneca can still rally from $184.96, but the bullish case now depends on execution rather than a rerating story. The clean version of that case is straightforward: guidance holds, launches ...

S&P 500 with valuation, earnings, inflation, scenario probabilities, trigger levels, and institutional data updated for mid-2026.

S&P 500 with valuation, earnings, inflation, scenario probabilities, trigger levels, and institutional data updated for mid-2026.